Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is an Open-label, randomized study in Type 1 diabetics looking at exposure and response
(PK/PD) of TI using GEN2C Inhaler versus rapid acting analog.